관상동맥 우회술 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the coronary artery bypass grafting market size is expected to grow from USD 17.76 billion in 2025 to USD 18.57 billion in 2026 and is forecast to reach USD 24.20 billion by 2031 at 5.44% CAGR over 2026-2031.

This report is Segmented by Procedure Type (On-Pump CABG, Off-Pump CABG, and More), Product and Services (Cardiopulmonary Bypass Machines, and More), Graft / Conduit Material (Saphenous Vein Grafts, and More), Surgery Complexity (Single Bypass, and More), End User (Hospitals, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Coronary Artery Bypass Grafting Market Trends and Insights

Rising Prevalence of Complex Multivessel CAD and Diabetes

Diabetes sharply increases vessel disease complexity, and patients with both conditions see better survival with surgery than with PCI.The International Diabetes Federation expects diabetic adults to climb to 783 million by 2045, with most of the growth in low- and middle-income countries. In parallel, Asia faces a projected 91.2% jump in cardiovascular mortality by 2050, keeping surgical demand on a steep upward slope. Because diabetic multivessel disease often exceeds SYNTAX 22, guidelines now direct such cases to heart teams for CABG referral. As screening improves and populations age, the coronary artery bypass grafting market gains a sizeable inflow of high-complexity candidates.

Aging Population in G-20 Economies Expanding Surgical Candidate Pool

Citizens aged 65 and older will represent 24.3% of the G-20 population by 2050. Older patients present diffuse disease and more left main involvement, both indications for complete surgical revascularization. Japan, Germany, Italy, and South Korea face the steepest demographic curves, while the U.S. training pipeline has doubled cardiothoracic residents since 2008. However, perfusionist numbers lag; half of the current U.S. workforce may retire by 2031. This imbalance fuels wait lists in Canada and the United Kingdom, intensifying pressure on hospitals to streamline case scheduling.

PCI Drug-Eluting Stent Iterations Lowering Repeat-Intervention Rates

Biodegradable-polymer stents cut four-year major adverse events to 14.2% from 23.0% in recent randomized work. With second-generation everolimus devices delivering sub-10% five-year failure, intermediate SYNTAX cases now lean toward PCI. Johnson & Johnson's 2024 purchase of Shockwave Medical adds lithotripsy that lets interventionalists tackle calcified lesions once sent to surgery. As the technology diffuses, the coronary artery bypass grafting market faces gradual patient leakage in Western referral patterns.

Other drivers and restraints analyzed in the detailed report include:

1. Guideline Preference for CABG Over PCI in High SYNTAX-Score Disease
2. Transition to Mini-Sternotomy and Robotic CABG Unlocking Day-7 Discharge
3. Limited Global Stock of CABG-Skilled Surgeons and Perfusionists

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

On-pump techniques retained 54.73% of revenue in 2025, maintaining the largest coronary artery bypass grafting market share, while the coronary artery bypass grafting market size for minimally invasive and robotic platforms is set to expand at a 9.24% CAGR through 2031. Hospitals value on-pump CABG for reliable myocardial protection when tackling three-vessel disease. Off-pump surgery holds niche appeal for calcified aortas but shows no survival edge in pooled data. Robotic systems close the cosmetic gap with PCI, reducing sternotomy discomfort and freeing ICU beds within 48 hours. Training curves have shortened to roughly 20 cases, and new leasing models spread capital outlays across five-year horizons.

Growth in robotic procedures also enables select cases in ambulatory centers, especially single- or double-vessel disease with preserved ventricular function. CMS pays a single bundled rate, so facilities that discharge on or before postoperative day 3 keep more of the margin. As hospitals chase these savings, the phrase coronary artery bypass grafting market will increasingly denote an ecosystem where acuity stratification, not volume, drives revenue.

Heart positioners and tissue stabilizers led 2025 sales at 26.63%, but endoscopic harvesting devices will grow fastest at 8.13% through 2031. Their use drops leg-wound infection to below 2% and trims operative time by nearly 25 minutes in contemporary series. Cardiopulmonary bypass consoles face elongated replacement cycles-often exceeding 15 years-as vendors deliver modular oxygenator upgrades. Services tied to those consoles generate 30% of Getinge's cardiovascular revenue, smoothing demand across purchase cycles.

Anastomosis assist tools gain traction in robotic cases where instrument articulation is limited. Meanwhile, regional suppliers compete on cannula price, especially in India and Brazil, although U.S. centers pay a premium for heparin-bonded tubing that reduces hemolysis. Vendor consolidation continues; 62% of U.S. programs have trimmed their supplier list by at least 20% since 2021. This shift concentrates bargaining power and reinforces the dominance of multinational brands in the coronary artery bypass grafting market.

Complete Report Scope:

• By Procedure Type
  • On-pump CABG
  • Off-pump CABG
  • Minimally Invasive and Robotic-Assisted CABG
• By Product and Services
  • Cardiopulmonary Bypass Machines
  • Endoscopic Vessel Harvesting Systems
  • Heart Positioners & Tissue Stabilizers
  • Cannulas & Tubing Sets
  • Anastomosis Assist Devices
  • Services
  • Others
• By Graft / Conduit Material
  • Saphenous Vein Grafts
  • Internal Thoracic Artery Grafts
  • Radial Artery Grafts
  • Synthetic & Bio-engineered Grafts
• By Surgery Complexity
  • Single Bypass
  • Double Bypass
  • Triple Bypass
  • Quadruple & Higher
• By End User
  • Hospitals
  • Cardiac Centres & Clinics
  • Ambulatory Surgical Centres
  • Academic & Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 36.44% of 2025 revenue, rooted in roughly 200,000 annual U.S. procedures and early adoption of robotic consoles. Medicare reimbursement for multi-arterial grafting plus bundled payments under BPCI Advanced keep profit pools attractive despite stable case counts. Canada's perfusionist shortage produced 80 surgery-delay deaths in Quebec during the 18 months to mid-2024. Mexico continues to send complex cases north, bolstering regional volumes.

Asia-Pacific will record a 7.03% CAGR through 2031, the fastest of any region, as diabetes prevalence and infrastructure investment collide. China has added more than 200 cardiac surgery units since 2020; many feature hybrid suites capable of both CABG and transcatheter valve work. India's market splits between high-volume private chains in metros and resource-limited public hospitals elsewhere. Japan and South Korea aim to mitigate workforce gaps by expanding integrated six-year cardiothoracic residencies, helping preserve procedure capacity as populations age past 30% elderly.

Europe trails in growth but retains significant volume, led by Germany's 70,000 annual cases. The EU Emissions Trading System now pressures hospitals to curb OR carbon output, nudging procurement toward reusable instruments. The United Kingdom adopted the VEST external stent in five trusts, setting precedent for technology appraisal across the bloc. Gulf nations in the Middle East recruit international surgical teams to build regional hubs, while Brazil and Argentina ramp private-sector robotic programs to serve patients once bound for U.S. centers.

1. Abbott Laboratories
2. Artivion
3. AtriCure
4. B. Braun
5. Boston Scientific
6. Edward Lifesciences
7. Genesee Biomedical
8. Getinge
9. Karl Storz
10. LeMaitre Vascular
11. LivaNova
12. Medtronic
13. MicroPort
14. Novadaq Technologies
15. Stryker
16. Teleflex
17. Terumo
18. Vitalitec
19. W. L. Gore & Associates

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Complex Multivessel CAD and Diabetes
  • 4.2.2 Ageing Population in G-20 Economies Expanding Surgical Candidate Pool
  • 4.2.3 Guideline Preference for CABG Over PCI In High SYNTAX-Score Disease
  • 4.2.4 Transition to Mini-Sternotomy & Robotic CABG Unlocking Day-7 Discharge
  • 4.2.5 Commercialization Of External Stents for Saphenous Vein Grafts Enhancing Durability
  • 4.2.6 Regional Bundled-Payment Pilots Rewarding Multi-Arterial Grafting Outcomes
• 4.3 Market Restraints
  • 4.3.1 PCI Drug-Eluting Stent Iterations Lowering Repeat-Intervention Rates
  • 4.3.2 Limited Global Stock of CABG-Skilled Surgeons & Perfusionists
  • 4.3.3 Procedural CO2 Footprint Scrutiny in EU ETS Phase-In
  • 4.3.4 Rising U.S. Tariffs on Precision CABG Components Inflating ASPs
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Procedure Type
  • 5.1.1 On-pump CABG
  • 5.1.2 Off-pump CABG
  • 5.1.3 Minimally Invasive and Robotic-Assisted CABG
• 5.2 By Product and Services
  • 5.2.1 Cardiopulmonary Bypass Machines
  • 5.2.2 Endoscopic Vessel Harvesting Systems
  • 5.2.3 Heart Positioners & Tissue Stabilizers
  • 5.2.4 Cannulas & Tubing Sets
  • 5.2.5 Anastomosis Assist Devices
  • 5.2.6 Services
  • 5.2.7 Others
• 5.3 By Graft / Conduit Material
  • 5.3.1 Saphenous Vein Grafts
  • 5.3.2 Internal Thoracic Artery Grafts
  • 5.3.3 Radial Artery Grafts
  • 5.3.4 Synthetic & Bio-engineered Grafts
• 5.4 By Surgery Complexity
  • 5.4.1 Single Bypass
  • 5.4.2 Double Bypass
  • 5.4.3 Triple Bypass
  • 5.4.4 Quadruple & Higher
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Cardiac Centres & Clinics
  • 5.5.3 Ambulatory Surgical Centres
  • 5.5.4 Academic & Research Institutes
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 France
    • 5.6.2.3 United Kingdom
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East & Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Abbott
  • 6.3.2 Artivion
  • 6.3.3 AtriCure
  • 6.3.4 B. Braun Melsungen
  • 6.3.5 Boston Scientific
  • 6.3.6 Edwards Lifesciences
  • 6.3.7 Genesee Biomedical
  • 6.3.8 Getinge (Maquet)
  • 6.3.9 KARL STORZ
  • 6.3.10 LeMaitre Vascular
  • 6.3.11 LivaNova PLC
  • 6.3.12 Medtronic
  • 6.3.13 MicroPort
  • 6.3.14 Novadaq Technologies
  • 6.3.15 Stryker
  • 6.3.16 Teleflex
  • 6.3.17 Terumo Corporation
  • 6.3.18 Vitalitec
  • 6.3.19 W. L. Gore & Associates

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment